NIH news from FiercePharma
News
Avastin-Lucentis trial may reshape pharma
We thought the head-to-head trial of Avastin and Lucentis for age-related macular degeneration was a big deal for Genentech, which Read more...
Seroquel researcher got cash from AZ
Sen. Charles Grassley's hall of shame: The chairman of the Senate Finance Committee, who's been trying to rally support for a bill requiring drug and device makers to disclose anything of value Read more...
NIH launches Avastin-Lucentis trial
Gentlemen (and ladies), start your eye injections. In other Avastin news, the big trial pitting the cancer drug against Genentech sister med Lucentis is now underway. Sponsored by the National Read more...
Canada to decide Lucentis' fate
The Lucentis versus Avastin match has moved to Canada. Officials there are arguing Read more...
Novartis drug cuts hip-fracture deaths
Big kudos to the Novartis osteoporosis drug Reclast: A New England Journal of Medicine study showed that patients with broken hips were more likely to survive if they were given a yearly dose of the Read more...
Study: 86% of docs cut Zyprexa use
Whoever said there's no such thing as bad publicity never worked in pharma. The latest proof of bad news-related suffering: A new report on antipsychotic drugs finds Janssen's Risperdal and Read more...
Stent-makers get more bad news
Go ahead, kick them while they're down. Britain's National Health Service may stop paying for drug-coated stents, products that already are Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends